Published in J Clin Oncol on August 31, 2009
Trends in radical prostatectomy: centralization, robotics, and access to urologic cancer care. Cancer (2011) 3.13
Exploring the burden of inpatient readmissions after major cancer surgery. J Clin Oncol (2014) 2.84
Association of distance from a transplant center with access to waitlist placement, receipt of liver transplantation, and survival among US veterans. JAMA (2014) 1.95
Impact of procedure volumes and focused practice on short-term outcomes of elective and urgent colon cancer resection in Italy. PLoS One (2013) 1.43
National trends in resection of the distal pancreas. World J Gastroenterol (2012) 1.07
What factors influence minority use of National Cancer Institute-designated cancer centers? Cancer (2013) 0.95
Quality improvement of pancreatic surgery by centralization in the western part of the Netherlands. Ann Surg Oncol (2011) 0.91
Socioeconomic and racial differences in treatment for breast cancer at a low-volume hospital. Ann Surg Oncol (2011) 0.91
Cancer survivors' perceived need for supportive care and their attitude towards self-management and eHealth. Support Care Cancer (2014) 0.90
Care transitions between hospitals are associated with treatment delay for patients with muscle invasive bladder cancer. J Urol (2014) 0.89
Racial disparities in changing to a high-volume urologist among men with localized prostate cancer. Med Care (2011) 0.88
Distance as a Barrier to Cancer Diagnosis and Treatment: Review of the Literature. Oncologist (2015) 0.86
Fragmentation of Care after Surgical Discharge: Non-Index Readmission after Major Cancer Surgery. J Am Coll Surg (2016) 0.85
Variation in performance of candidate surgical quality measures for muscle-invasive bladder cancer by hospital type. BJU Int (2014) 0.84
Factors associated with use of preoperative chemoradiation therapy for rectal cancer in the Cancer Care Outcomes Research and Surveillance Consortium. Am J Clin Oncol (2013) 0.83
Does in-house availability of multidisciplinary teams increase survival in upper gastrointestinal-cancer? World J Gastrointest Oncol (2013) 0.81
Racial disparities in the use of cardiac revascularization: does local hospital capacity matter? PLoS One (2013) 0.81
Minimum volume standards in German hospitals: do they get along with procedure centralization? A retrospective longitudinal data analysis. BMC Health Serv Res (2015) 0.81
Centralization of services and reduction of adverse events in pancreatic cancer surgery. World J Surg (2013) 0.80
Quantifying Nonindex Hospital Readmissions and Care Fragmentation after Major Urological Oncology Surgeries in a Nationally Representative Sample. J Urol (2016) 0.79
Delay of Treatment Initiation Does Not Adversely Affect Survival Outcome in Breast Cancer. Cancer Res Treat (2015) 0.79
Surgical quality is more than volume: the association between changing urologists and complications for patients with localized prostate cancer. Health Serv Res (2014) 0.79
Economic evaluations on centralisation of specialised healthcare services: a systematic review of methods. BMJ Open (2016) 0.79
Causes, Timing, Hospital Costs and Perioperative Outcomes of Index vs Nonindex Hospital Readmissions after Radical Cystectomy: Implications for Regionalization of Care. J Urol (2016) 0.78
Does travel distance influence length of stay in elective pancreatic surgery? HPB (Oxford) (2013) 0.78
The impact of health insurance mandates on drug innovation: evidence from the United States. Eur J Health Econ (2013) 0.78
Centralization of cancer surgery: what does it mean for surgical training? J Clin Oncol (2009) 0.77
The Relationship between Centralization of Care and Geographic Barriers to Cystectomy for Bladder Cancer. Bladder Cancer (2016) 0.77
Laparoscopic pancreatoduodenectomy combined with a novel self-assessment system and feedback discussion: a phase 1 surgical trial following the IDEAL guidelines. Langenbecks Arch Surg (2016) 0.76
Physician-reported barriers to referring cancer patients to specialists: prevalence, factors, and association with career satisfaction. Cancer (2014) 0.75
Wait times from diagnosis to treatment in cancer. J Gynecol Oncol (2015) 0.75
Readmissions After Colon Cancer Surgery: Does It Matter Where Patients Are Readmitted? J Oncol Pract (2016) 0.75
Temporal trends in centralization and racial disparities in utilization of high-volume hospitals for lung cancer surgery. Medicine (Baltimore) (2017) 0.75
Hospital resource intensity and cirrhosis mortality in United States. World J Gastroenterol (2017) 0.75
Disparities in the Utilization of Laparoscopic Surgery for Colon Cancer in Rural Nebraska: A Call for Placement and Training of Rural General Surgeons. J Rural Health (2015) 0.75
Complex and Reoperative Colorectal Surgery: Setting Expectations and Learning from Experience. Clin Colon Rectal Surg (2016) 0.75
Multimorbidity and access to major cancer surgery at high-volume hospitals in a regionalized era. Am J Surg (2016) 0.75
Waiting time for cancer treatment and mental health among patients with newly diagnosed esophageal or gastric cancer: a nationwide cohort study. BMC Cancer (2017) 0.75
The Effects of Travel Burden on Outcomes After Resection of Extrahepatic Biliary Malignancies: Results from the US Extrahepatic Biliary Consortium. J Gastrointest Surg (2017) 0.75
Nationwide outcomes of nontrauma splenectomy. Surg Endosc (2014) 0.75
Is There a Rationale for Structural Quality Assurance in Esophageal Surgery? Visc Med (2017) 0.75
Hospital volume and surgical mortality in the United States. N Engl J Med (2002) 25.79
Should operations be regionalized? The empirical relation between surgical volume and mortality. N Engl J Med (1979) 11.10
Impact of hospital volume on operative mortality for major cancer surgery. JAMA (1998) 11.05
Relation of perioperative deaths to hospital volume among patients undergoing pancreatic resection for malignancy. Ann Surg (1995) 5.90
Selective referral to high-volume hospitals: estimating potentially avoidable deaths. JAMA (2000) 5.49
Does practice make perfect? Part I: The relation between hospital volume and outcomes for selected diagnostic categories. Med Care (1984) 4.31
Volume and outcome--it is time to move ahead. N Engl J Med (2002) 4.26
Importance of hospital volume in the overall management of pancreatic cancer. Ann Surg (1998) 4.19
Disparities in the utilization of high-volume hospitals for complex surgery. JAMA (2006) 3.35
Relation of hospital volume to colostomy rates and survival for patients with rectal cancer. J Natl Cancer Inst (2003) 3.21
Influence of hospital procedure volume on outcomes following surgery for colon cancer. JAMA (2000) 3.18
Correlation of travel time on roads versus straight line distance. Med Care Res Rev (1995) 2.98
Hospital volume and late survival after cancer surgery. Ann Surg (2007) 2.93
A hospital's annual rate of esophagectomy influences the operative mortality rate. J Gastrointest Surg (1999) 2.87
Hospital and surgeon procedure volume as predictors of outcome following rectal cancer resection. Ann Surg (2002) 2.71
Spatial patterns of hospital utilization: the impact of distance and time. Inquiry (1984) 2.48
Regionalization of high-risk surgery and implications for patient travel times. JAMA (2003) 2.41
Progressive specialization within general surgery: adding to the complexity of workforce planning. J Am Coll Surg (2005) 2.38
Hospital volume can serve as a surrogate for surgeon volume for achieving excellent outcomes in colorectal resection. Ann Surg (1999) 2.37
Statewide regionalization of pancreaticoduodenectomy and its effect on in-hospital mortality. Ann Surg (1998) 2.32
Perioperative mortality for pancreatectomy: a national perspective. Ann Surg (2007) 2.26
Hospital volume and mortality after pancreatic resection: a systematic review and an evaluation of intervention in the Netherlands. Ann Surg (2005) 2.21
Hospital volume influences outcome in patients undergoing pancreatic resection for cancer. West J Med (1996) 2.02
How many miles to the doctor? N Engl J Med (1983) 1.87
Relation between surgical volume and incidence of postoperative wound infection. N Engl J Med (1981) 1.87
Racial disparities in late survival after rectal cancer surgery. J Am Coll Surg (2006) 1.83
Trends in hospital and surgeon volume and operative mortality for cancer surgery. Ann Surg Oncol (2006) 1.58
Effect of hospital volume on outcome of pancreaticoduodenectomy in Italy. Br J Surg (2008) 1.50
Hospital volume and hospital mortality for esophagectomy. Cancer (2001) 1.47
Regional availability of high-volume hospitals for major surgery. Health Aff (Millwood) (2004) 1.41
The Leapfrog volume criteria may fall short in identifying high-quality surgical centers. Ann Surg (2003) 1.37
Trends and disparities in regionalization of pancreatic resection. J Gastrointest Surg (2007) 1.35
High volume centers for esophagectomy: what is the number needed to achieve low postoperative mortality? Dis Esophagus (2004) 1.33
Relation of surgeon and hospital volume to processes and outcomes of colorectal cancer surgery. Ann Surg (2006) 1.31
Effect of centralization of pancreaticoduodenectomy on nationwide hospital mortality and length of stay. Br J Surg (2007) 1.30
Is surgery getting safer? National trends in operative mortality. J Am Coll Surg (2002) 1.26
Effect of hospital caseload on long-term outcome after standardization of rectal cancer surgery at a national level. Br J Surg (2005) 1.24
What would be the effect of referral to high-volume hospitals in a largely rural state? J Rural Health (2004) 1.24
Impact of hospital procedure volume on surgical operation and long-term outcomes in high-risk curatively resected rectal cancer: findings from the Intergroup 0114 Study. J Clin Oncol (2004) 1.20
Effects of hospital volume on life expectancy after selected cancer operations in older adults: a decision analysis. J Am Coll Surg (2003) 1.15
Variations in treatment of rectal cancer: the influence of hospital type and caseload. Dis Colon Rectum (1997) 1.13
Impact of hospital case volume on short-term outcome after laparoscopic operation for colonic cancer. Surg Endosc (2005) 1.12
Influence of hospital volume on the frequency of abdominoperineal resection and long-term oncological outcomes in low rectal cancer. Eur J Surg Oncol (2007) 0.99
Hospital caseload and the results achieved in patients with rectal cancer. Br J Surg (2001) 0.98
Role of volume outcome data in assuring quality in HPB surgery. HPB (Oxford) (2007) 0.96
Hospital-to-hospital variation in lymph node detection after colorectal resection. Cancer (2004) 0.95
Oesophagectomy practice and outcomes in England. Br J Surg (2007) 0.91
Centralisation of oesophagogastric cancer services: can specialist units deliver? Ann R Coll Surg Engl (2006) 0.87
Delivering affordable cancer care in high-income countries. Lancet Oncol (2011) 12.79
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol (2007) 11.77
A national evaluation of the effect of trauma-center care on mortality. N Engl J Med (2006) 9.74
Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol (2004) 9.73
Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol (2007) 9.29
Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol (2003) 8.95
Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol (2008) 8.72
American Society of Clinical Oncology Statement on minimum standards and exemplary attributes of clinical trial sites. J Clin Oncol (2008) 4.79
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
Colon cancer survival is associated with decreasing ratio of metastatic to examined lymph nodes. J Clin Oncol (2005) 3.50
Excise, ablate or observe: the small renal mass dilemma--a meta-analysis and review. J Urol (2008) 3.46
Global gene expression profiling of circulating tumor cells. Cancer Res (2005) 3.41
Evaluating overall survival and competing risks of death in patients with localized renal cell carcinoma using a comprehensive nomogram. J Clin Oncol (2009) 3.38
Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1. J Clin Oncol (2007) 3.37
Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol (2008) 3.34
Accuracy of determining nodal negativity in colorectal cancer on the basis of the number of nodes retrieved on resection. Ann Surg Oncol (2003) 3.27
NCCN clinical practice guidelines in oncology: hepatobiliary cancers. J Natl Compr Canc Netw (2009) 3.25
Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy--an intergroup study. J Clin Oncol (2002) 3.25
American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes. J Clin Oncol (2014) 3.20
Trends in radical prostatectomy: centralization, robotics, and access to urologic cancer care. Cancer (2011) 3.13
Association of routine pretreatment magnetic resonance imaging with time to surgery, mastectomy rate, and margin status. J Am Coll Surg (2009) 2.79
Patients' decision-making process regarding participation in phase I oncology research. J Clin Oncol (2006) 2.72
Academic ranking score: a publication-based reproducible metric of thought leadership in urology. Eur Urol (2011) 2.51
Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. J Clin Oncol (2002) 2.41
Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol (2010) 2.41
Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol (2006) 2.29
Anatomic features of enhancing renal masses predict malignant and high-grade pathology: a preoperative nomogram using the RENAL Nephrometry score. Eur Urol (2011) 2.22
Small renal masses progressing to metastases under active surveillance: a systematic review and pooled analysis. Cancer (2011) 1.98
Longitudinal Data with Follow-up Truncated by Death: Match the Analysis Method to Research Aims. Stat Sci (2009) 1.92
Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone. Clin Colorectal Cancer (2008) 1.89
The continuum of care: a paradigm for the management of metastatic colorectal cancer. Oncologist (2007) 1.89
The culture of faith and hope: patients' justifications for their high estimations of expected therapeutic benefit when enrolling in early phase oncology trials. Cancer (2010) 1.84
Correlates of colorectal cancer screening compliance and stage of adoption among siblings of individuals with early onset colorectal cancer. Health Psychol (2002) 1.84
American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J Clin Oncol (2008) 1.80
Isolation and characterization of circulating tumor cells in patients with metastatic colorectal cancer. Clin Colorectal Cancer (2006) 1.72
Four-week course of radiation for breast cancer using hypofractionated intensity modulated radiation therapy with an incorporated boost. Int J Radiat Oncol Biol Phys (2007) 1.71
Efficacy of motivational interviewing for smoking cessation: a systematic review and meta-analysis. Tob Control (2010) 1.69
Facilitating informed decisions regarding microsatellite instability testing among high-risk individuals diagnosed with colorectal cancer. J Clin Oncol (2010) 1.69
The correlation between patient characteristics and expectations of benefit from Phase I clinical trials. Cancer (2003) 1.65
Factors affecting recovery of functional status in older adults after cancer surgery. J Am Geriatr Soc (2010) 1.56
Predictors of long-term outcomes in older breast cancer survivors: perceptions versus patterns of care. J Clin Oncol (2003) 1.54
NEDD9 promotes oncogenic signaling in mammary tumor development. Cancer Res (2009) 1.53
Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer. Cancer (2007) 1.52
Communication between physicians and older women with localized breast cancer: implications for treatment and patient satisfaction. J Clin Oncol (2002) 1.49
The National Cancer Institute-American Society of Clinical Oncology Cancer Trial Accrual Symposium: summary and recommendations. J Oncol Pract (2013) 1.48
Nephron-sparing management vs radical nephroureterectomy for low- or moderate-grade, low-stage upper tract urothelial carcinoma. BJU Int (2014) 1.47
Telomerase is frequently activated in tumors with microsatellite instability. Cancer Biol Ther (2004) 1.47
Cancer patient preferences for quality and length of life. Cancer (2008) 1.43
The base excision repair enzyme MED1 mediates DNA damage response to antitumor drugs and is associated with mismatch repair system integrity. Proc Natl Acad Sci U S A (2003) 1.41
A prospective feasibility trial to determine the significance of the sentinel node gradient in breast cancer: a predictor of nodal metastasis location. Cancer (2008) 1.41
Comparison of prostate cancer diagnosis in patients receiving unrelated urological and non-urological cancer care. BJU Int (2013) 1.41
Why Summary Comorbidity Measures Such As the Charlson Comorbidity Index and Elixhauser Score Work. Med Care (2015) 1.41
Correlation between financial relationships with commercial interests and research prominence at an oncology meeting. J Clin Oncol (2013) 1.40
Locoregional strategies for colorectal hepatic metastases. Clin Colorectal Cancer (2003) 1.39
UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clin Cancer Res (2005) 1.39
Fibroblast activation protein and its relationship to clinical outcome in pancreatic adenocarcinoma. Pancreas (2008) 1.38
Atomic bomb survivor cataract surgery prevalence data are consistent with non-zero threshold dose--Comment on article by Nakashima et al. 2013. Health Phys (2014) 1.38
Changing patterns of bone and brain metastases in patients with colorectal cancer. Clin Colorectal Cancer (2005) 1.37
Phase II trial of single agent Val-boroPro (Talabostat) inhibiting Fibroblast Activation Protein in patients with metastatic colorectal cancer. Cancer Biol Ther (2007) 1.35
Trends in centralization of cancer surgery. Ann Surg Oncol (2010) 1.35
The National Study on Costs and Outcomes of Trauma. J Trauma (2007) 1.34
Expectations of benefit in early-phase clinical trials: implications for assessing the adequacy of informed consent. Med Decis Making (2008) 1.34
The impact of trauma-center care on functional outcomes following major lower-limb trauma. J Bone Joint Surg Am (2008) 1.31
Proteomic analyses of pancreatic cyst fluids. Pancreas (2009) 1.29
A randomized trial of generic versus tailored interventions to increase colorectal cancer screening among intermediate risk siblings. Ann Behav Med (2009) 1.26
A preliminary investigation of the predictors of tanning dependence. Am J Health Behav (2008) 1.22
Association between VEGF splice isoforms and progression-free survival in metastatic colorectal cancer patients treated with bevacizumab. Clin Cancer Res (2012) 1.21
Preoperative delays in the US Medicare population with breast cancer. J Clin Oncol (2012) 1.19
Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma. J Clin Oncol (2003) 1.17
The American Society of Clinical Oncology's Blueprint for Transforming Clinical and Translational Cancer Research. J Clin Oncol (2012) 1.16
Multiple behavioral risk factors for colorectal cancer and colorectal cancer screening status. Cancer Epidemiol Biomarkers Prev (2007) 1.16
Impact of tumor location on nodal evaluation for colon cancer. Dis Colon Rectum (2008) 1.15
Lymph node dissection: is it diagnostic or therapeutic? J Clin Oncol (2003) 1.14
Radiation Therapy Oncology Group 0247: a randomized Phase II study of neoadjuvant capecitabine and irinotecan or capecitabine and oxaliplatin with concurrent radiotherapy for patients with locally advanced rectal cancer. Int J Radiat Oncol Biol Phys (2011) 1.13
Visual acuity change and mortality in older adults. Invest Ophthalmol Vis Sci (2005) 1.13
Understanding how out-of-pocket expenses, treatment value, and patient characteristics influence treatment choices. Oncologist (2010) 1.12
Research participants' high expectations of benefit in early-phase oncology trials: are we asking the right question? J Clin Oncol (2012) 1.11
Understanding intention to undergo colonoscopy among intermediate-risk siblings of colorectal cancer patients: a test of a mediational model. Prev Med (2003) 1.10
Patient and provider characteristics that affect the use of axillary dissection in older women with stage I-II breast carcinoma. Cancer (2002) 1.08
Cost concerns of patients with cancer. J Oncol Pract (2013) 1.07
Advanced imaging modalities in early stage breast cancer: preoperative use in the United States Medicare population. Ann Surg Oncol (2012) 1.07
A novel Cas family member, HEPL, regulates FAK and cell spreading. Mol Biol Cell (2008) 1.07
Phosphorylation of Akt (Ser473) predicts poor clinical outcome in oropharyngeal squamous cell cancer. Cancer Epidemiol Biomarkers Prev (2007) 1.06
Using health communication best practices to develop a web-based provider-patient communication aid: the CONNECT study. Patient Educ Couns (2008) 1.05
Age, tumor size and relative survival of patients with localized renal cell carcinoma: a surveillance, epidemiology and end results analysis. J Urol (2008) 1.05
Use of systemic therapy and factors affecting survival for patients undergoing cytoreductive nephrectomy. BJU Int (2009) 1.05
Ongoing challenge of stage II colon cancer. J Clin Oncol (2011) 1.04
Prospective case-control study of serum mullerian inhibiting substance and breast cancer risk. J Natl Cancer Inst (2009) 1.04
Surgical treatment of liver metastases. Semin Oncol (2002) 1.04
Circulating tumor cells: evolving evidence and future challenges. Oncologist (2009) 1.04
Targeting signal transduction pathways in colorectal cancer--more than skin deep. J Clin Oncol (2005) 1.04
Cancer patients' trade-offs among efficacy, toxicity, and out-of-pocket cost in the curative and noncurative setting. Med Care (2013) 1.04
Phase I trial of preoperative hypofractionated intensity-modulated radiotherapy with incorporated boost and oral capecitabine in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys (2007) 1.03